Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial

Fazel, Farhad; Nikpour, Hossein; Pourazizi, Mohsen

doi:10.1155/2020/6794391

Cited by 11 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study there was no significant variation among studied group in IOP reduction (p = 0.302), a similar finding by Fazel et al. 11 Also, Hsu et al found more reduction of IOP in the dorzolamide-timolol group in comparison with placebo, but variation was not statistically significant (P =0.24). 9 In contrary to Mirshahi et al who found that IOP was decreased in eyes that received timolol-dorzolamide, not in eyes that received IVB alone.…”

Section: Octsupporting

confidence: 84%

The Additive Effect of Topical Dorzolamide-Timolol with Intravitreal Ranibizumab Injection in Diabetic Macular Edema

Gadwal¹,

Madbouly²,

Mansour³

2022

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

Background: Intravitreal injection of anti-vascular endothelial growth factor agents is the main therapeutic option in treatment of diabetic macular edema (DME). Some eyes with DME persistent despite frequent injections. Adjuvant therapies that further reduce edema may improve visual outcome. Aim of The Work:To assess influence of topical dorzolamide-timolol with intravitreal ranibizumab injection (IVR) on anatomical and functional outcomes in DME. Patients and Methods: This prospective cohort study included thirty patients (30 eyes) having type 2 DM, aged 45-60 years, all eyes have NPDR with DME. They were divided into 2 groups according to treatment protocol: Group 1: 15 patients (15 eyes) received IVR (3 monthly injection of Lucentis® 0.5 mg/0.05 ml) and adjuvant topical dorzolamide-timolol (Xolamol™ eye drops twice daily). Group 2: 15 patients (15 eyes) received IVR only. Results: Mean BCVA changes were significant in both groups, it changed from 0.93 ± 0.23 logMAR at baseline to 0.73 ± 0.27 (P < 0.001) in group 1 & from 0.93 ± 0.3 logMAR to 0.8 ± 0.33 (P = 0.001) in group 2. changes in mean CMT were significant in both groups, it changed from 568.67 ± 145.76 at baseline to 384 ± 110.63 (P ˂ 0.001) in group 1 & from 513.4 ± 114.54 at baseline to 387.87 ± 119.52 (P ˂ 0.001) in group 2, at 4th month. Comparing group 1 and group 2 from baseline to the last visit, mean changes in BCVA was 0.2 vs 0.13, mean changes in CMT was -184.67μm vs -125.53μm but the differences between the 2 groups were not statistically significant. Conclusion: Adjuvant topical dorzolamide -timolol with IVR had additive effects, but not a statistically significant, on IVR in the treatment of DME over a 4-month-course.

show abstract

Section: Octsupporting

confidence: 84%

The Additive Effect of Topical Dorzolamide-Timolol with Intravitreal Ranibizumab Injection in Diabetic Macular Edema

Gadwal¹,

Madbouly²,

Mansour³

2022

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

show abstract

“…Badawi et al suggested that topical dorzolamide without IVB injection can be effective in CMT reduction and BCVA improvement (11). Three other studies have investigated the e cacy of topical aqueous suppressants combined with intravitreal anti-VEGF injection in treating DME (12,13,18). In line with our results, Fazel et al showed that the adjuvant administration of topical dorzolamide was ineffective in improving the therapeutic effects of IVB injection (12).…”

Section: Discussionmentioning

confidence: 99%

“…Three other studies have investigated the e cacy of topical aqueous suppressants combined with intravitreal anti-VEGF injection in treating DME (12,13,18). In line with our results, Fazel et al showed that the adjuvant administration of topical dorzolamide was ineffective in improving the therapeutic effects of IVB injection (12). In contrast, Mirshahi et al reported a decrease in CMT and improvement in BCVA by adding timolol-dorzolamide eye drop to IVB injection (13).…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies pointed out the effectiveness of dorzolamide in the treatment of macular edemas of various etiologies (5)(6)(7)(8)(9)(10). However, the data concerning its e cacy in the treatment of DME is controversial (11)(12)(13). It was reported that adjuvant administration of topical timolol-dorzolamide with intravitreal bevacizumab (IVB) injection might be bene cial in reducing central macular thickness (CMT) (13).…”

Section: Introductionmentioning

confidence: 99%

“…It was reported that adjuvant administration of topical timolol-dorzolamide with intravitreal bevacizumab (IVB) injection might be bene cial in reducing central macular thickness (CMT) (13). A more recent study reported that adjuvant administration of topical dorzolamide with IVB injection had no additive effects on the treatment of DME (12).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Topical Dorzolamide as Adjunctive Treatment with Intravitreal Bevacizumab in Bilateral Diabetic Macular Edema (DME)

Sadr,

Sargazi,

Banaie

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is accepted as the gold standard treatment for center-involving diabetic macular edema (CI-DME). Adjunctive administration of topical dorzolamide may enhance the therapeutic effects of anti-VEGF agents. In this study, we compared the efficacy of topical dorzolamide in addition to intravitreal injection of bevacizumab (IVB) versus IVB alone in patients with bilateral DME. Methods: This randomized, double-blind, contralateral eye study included 50 eyes of 25 patients with bilateral DME. All eyes received three consecutive monthly injections of IVB. For each patient, one eye was randomized to instill dorzolamide eye drops three times a day as an intervention, and the control eye received artificial tear drops as a placebo. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were evaluated before starting treatment and then monthly for the next 3 months. Results: Among 25 included patients, the average age was 56.64 ± 7.97 years, and 48% were female. BCVA did not improve significantly in any groups (P > 0.05). The present study showed a decrease in CMT in both study groups (P < 0.001). IOP decreased significantly only in patients receiving dorzolamide (P < 0.001). No significant difference was observed in terms of BCVA and CMT between the intervention and control groups (P > 0.05). However, IOP was significantly lower in patients receiving topical dorzolamide compared to the control group (P < 0.001). Conclusions: The results of the present study indicate that adjunctive administration of topical dorzolamide does not have an additive effect on CMT and BCVA improvement compared to IVB monotherapy.

show abstract

The effect of combination therapy with intravitreal bevacizumab and topical timolol–dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial

Fekri,

Rabiei,

Hooshmandi

et al. 2024

Int Ophthalmol

View full text Add to dashboard Cite

Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial

Cited by 11 publications

References 23 publications

The Additive Effect of Topical Dorzolamide-Timolol with Intravitreal Ranibizumab Injection in Diabetic Macular Edema

The Additive Effect of Topical Dorzolamide-Timolol with Intravitreal Ranibizumab Injection in Diabetic Macular Edema

Topical Dorzolamide as Adjunctive Treatment with Intravitreal Bevacizumab in Bilateral Diabetic Macular Edema (DME)

The effect of combination therapy with intravitreal bevacizumab and topical timolol–dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial

Contact Info

Product

Resources

About